Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session

Dawn of a new era: ctDNA-based biomarker detection for cancer diagnosis, response monitoring, and minimal residual disease

About This Webinar

Sponsored by: Burning Rock DX

Cancer detection and monitoring is changing and creating huge industry excitement for liquid biopsy-based screening and surveillance in solid tumors for novel precision drug development and access. Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in various body effluents instead of a fragment of cancer tissue. However, detecting ctDNA from solid tumors is a particularly difficult challenge, requiring advanced technical skills for test sensitivity optimization and precise data interpretation, especially for the ctDNA-based Minimal residual disease (MRD) detection. In this webinar, Burning Rock Dx, working with its Biopharma partner, will discuss current advantages and outlook of liquid biopsy and MRD testing in the pharmaceutical industry.

Privacy Policy

Who can view: Everyone
Webinar Price: Free
Webinar ID: 18c279e27f76
Featured Presenters
Webinar hosting presenter
Senior Director, Translational Medicine, Cogent Biosciences
Dr. Chu has more than 20 years of biomarker research and CDx development experience in the pharmaceutical industry. Before joining Cogent Biosciences, he headed the clinical biomarker team at Luzsana Biotech (Hengrui USA) and oversaw the strategies on the CDx development path for oncology and non-oncology pipelines. He joined Sanofi in 2000 and led research teams in proteomics, antibody drug discovery, biomarker, and clinical bioanalysis for over twenty years.
Webinar hosting presenter
Chief Technology Officer, Burning Rock Biotech
Dr. Zhihong (Joe) Zhang has served as Burning Rock's chief technology officer since March 2016. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000 and a Ph.D. in molecular genetics and microbiology from Duke University in 2005. After receiving his Ph.D., Joe landed a position in the genome science department of Howard Hughes Institute of Medicine at the University of Washington as a Senior Researcher. Before joining Burning Rock, Joe was a staff scientist of Illumina, Inc., and experienced in leading cross-functional project teams including marketing, operation, customer solution, bioinformatics, and software for several successfully launched products, including Infinium Omni 2.5M-8, 5M-4 gene sub-typing chip, TruSeq Dual Index Sequencing, TruSeq DNA Ht, TruSeq Stranded RNA HT, TruSeq Exome, TruSeq Synthetic Long-Read DNA.